Drug Profile
Research programme: MEK kinase inhibitors - Array BioPharma
Alternative Names: AR 00241389; ARRY-241389Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Novartis
- Class Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 13 Jul 2010 Preclinical development is ongoing in USA